NCT00445666: Tumor-Infiltrating Lymphocytes in Treating Patients With Persistent or Recurrent B-Cell Non-Hodgkin's Lymphoma, Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia or Multiple Myeloma After a Previous Donor Stem Cell Transplant |
|
|
| Active, not recruiting | 1 | 36 | US | graft-versus-tumor induction therapy, therapeutic tumor infiltrating lymphocytes, cytogenetic analysis, fluorescence in situ hybridization, microarray analysis, polymerase chain reaction, flow cytometry, immunoenzyme technique, immunohistochemistry staining method, immunologic technique, laboratory biomarker analysis, biopsy, conventional surgery | National Cancer Institute (NCI) | Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm | | | | |
NCT02339181: A Study of GDC-0199 (ABT-199) in Combination With Obinutuzumab in Patients With Chronic Lymphocytic Leukemia |
|
|
| Recruiting | 1 | 70 | US, Europe | GDC-0199 (ABT-199), Obinutuzumab | Hoffmann-La Roche, Accord Healthcare, Inc., AbbVie (prior sponsor, Abbott), Apotex Corporation, Alkem Laboratories Ltd | Lymphocytic Leukemia, Chronic | 01/15 | 11/16 | | |